Exciting News in Bioproduction! We're pleased to share a recent success with ProteoNic's 2G UNic® vector technology, highlighted in the publication: "Development of a 10 g/L Process for a Difficult-to-Express Multispecific Antibody Format Using a Holistic Process Development Approach." Key benefits of using our 2G UNic™ technology in this project include: - Improved Stability: Enhanced stable cell line production. - High Efficiency: Achieved a 10 g/L process for complex antibodies. - Cost-Effective Scaling: Streamlined and cost-efficient scale-up for large-scale manufacturing. This achievement shows the positive impact of our 2G UNic® vector technology in developing new biological therapeutics. Read the full publication for more details! https://lnkd.in/esvPdT_Y #Bioproduction #Biotechnology #Therapeutics #ProteoNic #2GUNic
Over ons
ProteoNic is a biotechnology company active in development and licensing of DNA technology for cell line generation and recombinant protein production for pharmaceutical applications. We offer premium vector technology that substantially boosts production levels of therapeutic proteins and other biologics. Cost savings are immediate and sizeable, freeing up production capacity and enabling commercially viable production of difficult to express proteins. ProteoNic’s 2G UNic™ drives higher production for all types of therapeutic protein products, including monoclonal antibodies, biosimilars and more difficult-to-express (DTE) proteins, such as Fc-fusion proteins and bi-specifics, contributing to their economic viability. Our patented technology does not require modifications to existing production systems or work flows and is compatible with all production cell lines and expression systems used in the industry. Independent technical and commercial validation by third parties, including top tier biopharma, demonstrates severalfold productivity level increases that translate into multi-million Euros in annual cost savings. The technology has wide ranging potential to boost production efficiencies in other important applications, including viral vector production, protein production in yeast and technologies which impact product quality. The company is headquartered at the BioScience Park in Leiden, the Netherlands and has a Boston, USA office for Business Development in the North American market.
- Website
-
http://www.proteonic.nl
Externe link voor ProteoNic
- Branche
- Biotechnologisch onderzoek
- Bedrijfsgrootte
- 11 - 50 medewerkers
- Hoofdkantoor
- Leiden, Nederland
- Type
- Particuliere onderneming
- Specialismen
- enabling technology for recombinant protein production yield enhancement
Locaties
-
Primair
Routebeschrijving
J.H. Oortweg 19-21
Leiden, Nederland 2333CH, NL
-
Routebeschrijving
Medewerkers van ProteoNic
Updates
-
A very nice concise introduction to our 2G UNic vector technology by Jonathan Frampton #2GUNicVectorTechnology #Bioproduction #Bioprocess #ViralVectors
Afternoon, I thought I'd share a short video introducing Proteonic's groundbreaking 2G UNic vector technology. It is designed to significantly enhance protein production titers and increase viral vector titers for Lentivirus and AAV. What is 2G UNic Vector Technology? - Our 2G UNic technology is composed of optimized genetic elements that can be paired with any promoter to boost both transcription and translation, leading to higher yields and more efficient production processes. Key Features: - Dual-Promoter System: Patented design that recruits transcriptional machinery for a significant increase in transcription. - Epigenetic Optimization: Ensures stable open chromatin structure. - Optimized 5’ UTR: Forms a 2D RNA hairpin structure to recruit ribosomes, enhancing RNA translation and stability. Whether you’re looking to boost protein expression or increase viral vector titers, our 2G UNic technology offers a powerful solution to enhance your research and production processes. Feel free to contact me to learn more 😁 #bioprocess #viralvectors #contactme
-
In case you missed it last week, our webinar by Jonathan Frampton is now available to view here: https://lnkd.in/e_7Hz9TQ Listen to our insightful webinar where we delve into the challenges facing viral vector manufacturing in CGT. - Understand viral vector challenges - Discover innovative manufacturing solutions - Enhance capacity with advanced technologies
-
-
We're pleased to be attending and partnering at #BIO2024! Please connect with the team (Jonathan Frampton & Mark Posno) in the BIO One-on-One Partnering system. #partnering #2GUNic #BIO2024
-
-
Exciting news! Join us on May 23 for a thought-provoking webinar led by Jonathan Frampton. Discover: - Comprehensive insights into the nuanced challenges of viral vector manufacturing, with practical optimization strategies to meet increasing demands effectively. - Exploration of innovative technologies revolutionizing viral vector manufacturing, unlocking cutting-edge solutions to enhance capacity and efficiency. - Deep dive into advancements in bioprocessing, automation, and vector technology, aimed at improving manufacturing capacity while upholding stringent quality standards. Don't miss out on this opportunity to stay ahead in the field of cell and gene therapy production. Register now! #ViralVector #CellTherapy #GeneTherapy #Bioprocessing #2GUNIC #Webinar
Deze content is hier niet beschikbaar
Open deze content en meer in de LinkedIn-app
-
Excited for the start of EBD Group's #AsiaBIO today in Singapore. Please connect via the app to meet onsite or next week virtually. Jonathan Frampton is onsite to share our new developments covering our CHO-2G UNic, LV-2G UNic and AAV-2G UNic vector technology. #partnering #asiabio #proteinproduction #viralvectors
-
-
We are pleased to be attending EBD Group's #AsiaBIO partnering event this week in Singapore. Please connect to Jonathan Frampton via the partnering event if you would like to meet onsite. Learn more about our LV-2G UNic Early Access Program and/or our CHO-2G UNic vector technology for boosting your protein titers. #AsiaBio #2GUNic #ViralVectors #Bioproduction
-
-
If you're attending EBD Group's #AsiaBio it is a great opportunity to connect with Jonathan Frampton to learn about how our LV-2G UNic is being applied to boost lentiviral titers to improve manufacturing capacity and cost for cell and gene therapy programs. Don't miss out on the chance to register for our Viral Vector Early Access Program: https://lnkd.in/e_RAum9m
I'm getting ready for EBD Group's AsiaBio, Singapore, next week (April 24-25), and looking forward to being a part of it. Excited to get started with the mingling, meeting new people and sharing how ProteoNic's 2G UNic vector technology could help your protein or viral vector production. Feel free to connect via the networking app. Now, here's the really juicy part: I'll be bringing the latest and greatest from ProteoNic. Get ready for some exciting updates, including insider info on our Early Access Program for Viral Vector 2G UNic technology. If you're gonna be at AsiaBio, give me a shout! Let's catch-up, share a tea/beer/wine/... and have fun. See you there! 👋 #AsiaBio #BiotechBonanza #2GUNic #NetworkingNinja #ProteonicParty
-
-
🌟 Exciting Announcement: ProteoNic unveils LV-2G UNic® Early Access Program! - Revolutionizing lentivirus manufacturing - Achieve remarkable enhancements in titers - Substantial improvements in cost efficiency - Seamless integration into existing systems - Join us in shaping the future of biologics production! For more info and to sign up, visit https://lnkd.in/e_RAum9m #Biotech #Innovation #LV2GUNic #EarlyAccessProgram 🧬🔬
Boosting protein production - ProteoNic BioSciences
https://proteonic.nl
-
Exciting partnership announcement: ProteoNic partners with Ginkgo Bioworks, Inc. (NYSE: DNA). - Access to ProteoNic's cutting-edge 2G UNic® vector technology for protein production and novel viral vector technology for cell and gene therapy applications for Ginkgo Bioworks’ customers. - ProteoNic joins the Ginkgo Technology Network, enhancing innovation in R&D programs. - CEO @Frank Pieper highlights strategic alignment with ProteoNic's mission to support clients in biologics manufacturing. - Synergy between ProteoNic's premium technology and Ginkgo Bioworks’ network promises enhanced solutions and value for customers across various biotech sectors. Stay tuned for more updates on our journey with Ginkgo Bioworks! https://lnkd.in/dQCaGYZq #ProteoNic #GinkgoBioworks #Partnership #BiotechInnovation #VectorTechnology #CellTherapy #GeneTherapy #GinkgoTechnologyNetwork 🌱💼🧬
ProteoNic Announces Partnership with Ginkgo Bioworks and Joins the Ginkgo Technology Network - ProteoNic BioSciences
https://proteonic.nl